Accolade (NASDAQ:ACCD) Releases Earnings Results, Beats Estimates By $0.01 EPS

Accolade (NASDAQ:ACCD - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.01, Zacks reports. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%.

Accolade Trading Down 0.4 %

Shares of ACCD traded down $0.03 during midday trading on Friday, hitting $6.83. 11,364,956 shares of the stock were exchanged, compared to its average volume of 6,673,309. Accolade has a 52-week low of $3.08 and a 52-week high of $15.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72. The stock has a fifty day simple moving average of $3.73 and a 200 day simple moving average of $3.84. The firm has a market cap of $550.07 million, a P/E ratio of -6.63 and a beta of 2.08.

Insider Activity at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of Accolade stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $48,085.20. Following the completion of the transaction, the chief executive officer now directly owns 814,316 shares in the company, valued at approximately $2,931,537.60. This trade represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 40,881 shares of company stock worth $144,987. 8.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on ACCD shares. Morgan Stanley reduced their price objective on Accolade from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. Leerink Partnrs lowered Accolade from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Stephens cut their price objective on shares of Accolade from $10.00 to $8.00 and set an "overweight" rating for the company in a research report on Wednesday, October 9th. Stifel Nicolaus reiterated a "hold" rating and issued a $7.03 target price (down from $8.00) on shares of Accolade in a report on Thursday. Finally, Barclays dropped their price target on shares of Accolade from $5.50 to $5.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 9th. Ten investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $7.55.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.